FDA user fee bill deadline falls apart? Thousands of pink slips for FDA could be coming as Burr seeks to start anew
The battle over what to include in this latest round of user fee legislation — the industry money that pays for all biopharma drug and biologic reviews at the FDA and has to be reauthorized every five years — is coming to a head as Congress looks to meet an August recess deadline before the FDA has to send out thousands of warnings to much-needed reviewers that they’ll be soon laid off.
Not only would the FDA be forced to send the pink slips, but all current PDUFA deadlines would grind to a halt as the agency would no longer have the staff to meet its review deadlines.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.